INS and type 2 diabetes mellitus: Similarly, another meta‐analysis of four randomised clinical trials in people with T2D reported that over 40–72 weeks,53 tirzepatide was not associated with an increased risk of any type of cancer as compared to either insulin or placebo (risk ratio: 0.79, 95% CI: 0.24–2.56); however, when compared to placebo alone, a significantly lower risk of cancer was observed (0.35, 95% CI: 0.13–0.95).